Stanley Capital Partners hires two in drive for growth

"This represents a continuation to an already exciting start to 2023 for SCP with a strong platform for further growth, targeting an existing USD 5bn pipeline of potential deal activity,” a spokesperson for SCP told Unquote.

James Sexton, Stanley Capital Partners

Sexton will focus on SCP’s fundraising activities and joins from Investcorp, where he focused on primary, co-investment and secondaries fundraising. He also has prior fundraising and financing experience via roles with Aon Hewitt, BC Partners, OMERS and Rede Partners.

Fogtdal will support SCP in developing operational efficiencies to drive growth in its portfolio in his new role. He joins from advisory firm Alvarez & Marsal, where he was a director in the firm’s private equity services team. He has experience in transactions in the technology, industrial engineering, aerospace, B2B and B2C retail sectors.

SCP focuses on investments in European healthcare and resource efficiency-related businesses, targeting firms with EBITDA of USD 25m-USD 150m. It uses its SCP Digital platform to support the growth of its portfolio companies, aiming to build value through “digital potential”, according to its website.

The firm was founded in 2019 by James Brooks, Patrick Hargutt and Simon Cottle, who between them have amassed experience at PE firms including Hg, Centerbridge, Advent International and Ardian.

The GP’s exits to date include specialty pharmaceutical firm Noden Pharma, which the GP sold in 2022, generating returns of 6.7x and an IRR of 151%. Its current portfolio companies include prescription and OTC pharmaceuticals marketing firm Laboratoire XO, which it acquired from Novalpina Capital in 2022.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• People
• GPs
• UK / Ireland
• Healthcare
• Support services
• people moves
• United Kingdom